Yeah, it sounds like they had issues with the product design and had to go back to the drawing board.
A 10 patient feasibility study doesn't guarantee the product is flawless. Being sent back to the drawing board is always a real possibility at that stage - it sounds like that's what happened.
We want to get the design right. That's the purpose of this phase of development.
It's disappointing we didn't get it right the first time. But we are still a company where the flagship product is changing practice internationally, and still has a huge market that needs penetrating. We have some products in the pipeline that are still early in development. C'est la vie.
This is medical technology. This is how it works. The company is in a very safe position long term, which is much better than many other companies at this market cap.
Getting disillusioned, page-82
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.00 |
Change
-0.040(1.96%) |
Mkt cap ! $1.388B | |||
| Open | High | Low | Value | Volume |
| $2.02 | $2.04 | $1.99 | $1.661M | 826.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 3758 | $2.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.01 | 19265 | 19 |
View Market Depth
| Last trade - 15.26pm 18/11/2024 (20 minute delay) ? |
| PNV (ASX) Chart |